DOCSLIB.ORG

Bioprinting Landscape: Technology and Trends Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bioprinting Landscape: Technology and Trends Report April 2018 Bioprinting Landscape: Technology and Trends Report BROWN UNIVERSITY – SENIOR THESIS INQUIRY THOMSON, ANDREW Table of Contents Executive Summary ............................................................................................................... 4 Introduction .......................................................................................................................... 7 Value Proposition ..........................................................................................................................7 Research Approach ........................................................................................................................8 Secondary Research: Multiple Search Sources ................................................................................................... 9 Primary Research: Expert Interviews .................................................................................................................. 9 Section 1: Fundamental Bioprinting Information .................................................................. 11 Bioprinting Technology Overview ................................................................................................. 11 Bioprinting History ....................................................................................................................... 13 Terminology Clarification: Biofabrication, Bioprinting and Bioassembly ......................................... 17 Why Bioprinting? ......................................................................................................................... 17 Microtissue Construction Processes: Biomimicry, Self-assembly and Bioassembly ......................... 22 Short- and Long-Term Goals ......................................................................................................... 24 Short-Term Goals ............................................................................................................................................... 24 Long-Term Goals ................................................................................................................................................ 25 Section 2: Vascularized Tissues ............................................................................................. 26 The Vasculature Issue .................................................................................................................. 26 Human Vascular Anatomy Overview............................................................................................. 27 Arteries, Capillaries and Veins ...................................................................................................... 29 Lymphatic System ........................................................................................................................ 30 Micro-network Processes: Vasculogenesis and Angiogenesis ......................................................... 31 Vasculogenesis ................................................................................................................................................... 31 Angiogenesis ...................................................................................................................................................... 32 Section 3: Bioprinting Approaches and Modalities ................................................................ 34 Macro-network Definition ............................................................................................................ 34 Micro-network Definition ............................................................................................................. 35 Macro-network Approaches ......................................................................................................... 36 Scaffold-Based (SB) ............................................................................................................................................ 36 Droplet and Inkjet (DBB) ................................................................................................................................... 38 Microextrusion (MBB) ....................................................................................................................................... 42 Laser (LBB) .......................................................................................................................................................... 47 Stereolithography (SBB) .................................................................................................................................... 50 Scaffold-Free (SFB) ............................................................................................................................................. 51 Micro-Network Approaches ......................................................................................................... 55 Guided Organization .......................................................................................................................................... 55 In vivo Integration .............................................................................................................................................. 57 Section 4: The Bioprinting Industry ....................................................................................... 61 Andrew Thomson, April 2018 Not for public disclosure or reproduction without written consent 1 Market Overview and Macro-Trends ............................................................................................ 62 Industry Player Archetypes: Producers, End-Users and Watchers .................................................. 63 Industry Archetype: Producers .......................................................................................................................... 63 Industry Archetype: End-Users .......................................................................................................................... 64 Industry Archetype: Watchers .......................................................................................................................... 64 The Bioprinting Pathway .............................................................................................................. 65 Industry-Wide Technical Limitations ................................................................................................................ 65 Technical Limitation – Vascularization Issue .................................................................................................... 67 Technical Limitation – Characterization Issue .................................................................................................. 67 Value Chain and Administrative Considerations .............................................................................................. 69 Bioinks ................................................................................................................................................................ 70 Bioprinters .......................................................................................................................................................... 71 Tissue Producer Companies............................................................................................................................... 74 Bioprinted Tissue Products ................................................................................................................................ 77 Product Commercialization Timeline ................................................................................................................ 80 Funding and Workforce Development .............................................................................................................. 81 Collaborations .................................................................................................................................................... 83 Regulatory and Intellectual Property Concerns................................................................................................ 85 Potential Opportunity Areas......................................................................................................... 87 Potential Opportunity Area: Large-Diameter Vascular Grafts ......................................................................... 88 Potential Opportunity Area: Small-Diameter Vascular Grafts ......................................................................... 90 Conclusion and Future Directions ......................................................................................... 92 Section 1: Key Findings and Takeaways ......................................................................................... 93 Section 2: Key Findings and Takeaways ......................................................................................... 93 Section 3: Key Findings and Takeaways ......................................................................................... 94 Section 4: Key Findings and Takeaways ......................................................................................... 94 Bioprinting Pathway Conclusions .................................................................................................. 90 Characterization Issue Guideline ........................................................................................................................ 96 Bioink Developmental
Load more

Recommended publications
  • 3D Bioprinting of Human Tissues: Biofabrication, Bioinks, and Bioreactors
    International Journal of Molecular Sciences Review 3D Bioprinting of Human Tissues: Biofabrication, Bioinks, and Bioreactors Jianhua Zhang , Esther Wehrle, Marina Rubert and Ralph Müller * Institute for Biomechanics, ETH Zurich, Leopold-Ruzicka-Weg 4, 8093 Zurich, Switzerland; [email protected] (J.Z.); [email protected] (E.W.); [email protected] (M.R.) * Correspondence: [email protected] Abstract: The field of tissue engineering has progressed tremendously over the past few decades in its ability to fabricate functional tissue substitutes for regenerative medicine and pharmaceutical research. Conventional scaffold-based approaches are limited in their capacity to produce constructs with the functionality and complexity of native tissue. Three-dimensional (3D) bioprinting offers exciting prospects for scaffolds fabrication, as it allows precise placement of cells, biochemical factors, and biomaterials in a layer-by-layer process. Compared with traditional scaffold fabrication approaches, 3D bioprinting is better to mimic the complex microstructures of biological tissues and accurately control the distribution of cells. Here, we describe recent technological advances in bio-fabrication focusing on 3D bioprinting processes for tissue engineering from data processing to bioprinting, mainly inkjet, laser, and extrusion-based technique. We then review the associated bioink formulation for 3D bioprinting of human tissues, including biomaterials, cells, and growth factors selection. The key bioink properties for successful bioprinting of human tissue were summarized. After bioprinting, the cells are generally devoid of any exposure to fluid mechanical cues, such as fluid shear stress, tension, and compression, which are crucial for tissue development and function in Citation: Zhang, J.; Wehrle, E.; health and disease.
    [Show full text]
  • Cultured Meat Factories of the Future
    FEBRUARY 2021 FEBRUARY PIONEERING MEAT 2.0 We are developing the sustainable cultured meat factories of the future. These B2B factories target multi- species cell-based agriculture and 3D bioprinting to produce a range of cultured meat products, including steak. © 2021 ALL RIGHTS RESERVED WWW.MEATECH3D.COM 2 DISCLAIMERS This presentation was prepared Meat-Tech 3D Ltd. ("MeaTech" or reports filed in connection with the Company with the Israel the “Company”), and is given to you only for the provision of concise Securities Authority and the Tel Aviv Stock Exchange Ltd., including information for the sake of convenience, and may not be copied or warnings regarding forward-looking information, as defined in distributed to any other person. The data and information included the Securities Law, 5728-1968, included therein. The forward- in this presentation should not be interpreted as advice and should looking information in the presentation may not materialize, in not be relied on for any purpose. Such data and information should whole or in part, or may materialize differently than expected, or not be copied or used except as expressly permitted in writing. This may be affected by factors that cannot be assessed in advance. presentation does not purport to be comprehensive or to contain For the avoidance of doubt, it is clarified that the Company do not any and all information which might be relevant in connection undertake to update and/or modify the information included in with the making of a decision on an investment in securities of the presentation to reflect events and/or circumstances occurring the Company.
    [Show full text]
  • ICMRA Innovation Project 3D Bio-Printing Case Study: Summary of Discussions and Considerations for the New Informal Innovation Network1
    ICMRA Innovation Project 3D Bio-Printing Case Study: Summary of Discussions and Considerations for the New Informal Innovation Network1 EXECUTIVE SUMMARY The International Coalition of Medicines Regulatory Authorities (ICMRA) Innovation Project identified 3D printing, artificial intelligence and gene editing as emerging disruptive technologies that challenge traditional health product regulatory systems. In an attempt to identify novel regulatory approaches to license health products manufactured or developed through these technologies, the Innovation Project team launched a case study on 3D bio- printing. Health Canada led these discussions with the following ICMRA members participating: the Therapeutic Goods Administration (TGA) of Australia; the Agência Nacional de Vigilância Sanitária (ANVISA) of Brazil; the European Medicines Agency (EMA) of the European Union; the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency (MHLW/PMDA) of Japan; and the Health Sciences Authority (HSA) of Singapore. From a public health, biotechnology and tissue engineering perspective, engineered therapies for musculoskeletal and vascular applications are advancing to address patient treatment demands. A hypothetical 3D bio-printed human knee meniscus was chosen for this case study, based on the current developments seen in the field and in the literature. The goals of the case study were to better understand key challenges for regulating this product, identify emerging regulatory solutions, and suggest areas for further scientific and policy discussions. There are many components of 3D bio-printing that could require regulatory oversight. These may include the printer itself, software, production processes, living and non-living printing material, and the deployment of the technology. 3D bio-printing technology challenges regulators with respect to classification of the output, and regulating different models of manufacturing (centralized model versus point-of-care production).
    [Show full text]
  • 3D Bioprinting Strategies for the Regeneration of Functional Tubular Tissues and Organs
    bioengineering Review 3D Bioprinting Strategies for the Regeneration of Functional Tubular Tissues and Organs Hun-Jin Jeong 1 , Hyoryung Nam 2, Jinah Jang 2,3,4,5,* and Seung-Jae Lee 1,6,* 1 Department of Mechanical Engineering, Wonkwang University, 460, Iksan-daero, Iksan-si, Jeollabuk-do 54538, Korea; [email protected] 2 Department of Creative IT Engineering, Pohang University of Science and Technology, 77 Cheongam-Ro, Nam-Gu, Pohang, Gyeongbuk 37673, Korea; [email protected] 3 School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology, 77 Cheongam-Ro, Nam-Gu, Pohang, Gyeongbuk 37673, Korea 4 Department of Mechanical Engineering, Pohang University of Science and Technology, 77 Cheongam-Ro, Nam-Gu, Pohang, Gyeongbuk 37673, Korea 5 Institute of Convergence Science, Yonsei University, 50, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea 6 Department of Mechanical and Design Engineering, Wonkwang University, 460, Iksan-daero, Iksan-si, Jeollabuk-do 54538, Korea * Correspondence: [email protected] (J.J.); [email protected] (S.-J.L.) Received: 29 February 2020; Accepted: 30 March 2020; Published: 31 March 2020 Abstract: It is difficult to fabricate tubular-shaped tissues and organs (e.g., trachea, blood vessel, and esophagus tissue) with traditional biofabrication techniques (e.g., electrospinning, cell-sheet engineering, and mold-casting) because these have complicated multiple processes. In addition, the tubular-shaped tissues and organs have their own design with target-specific mechanical and biological properties. Therefore, the customized geometrical and physiological environment is required as one of the most critical factors for functional tissue regeneration. 3D bioprinting technology has been receiving attention for the fabrication of patient-tailored and complex-shaped free-form architecture with high reproducibility and versatility.
    [Show full text]
  • Bioethical and Legal Issues in 3D Bioprinting Anastasia Kirillova1,†,*, Stanislav Bushev2,†, Aydar Abubakirov1, Gennady Sukikh1
    PERSPECTIVE Bioethical and Legal Issues in 3D Bioprinting Anastasia Kirillova1,†,*, Stanislav Bushev2,†, Aydar Abubakirov1, Gennady Sukikh1 1National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov of the Ministry of Healthcare of Russian Federation, Moscow, 117513, Russia 2Department of Philosophy, Lomonosov Moscow State University, Moscow, 119991, Russia †These authors contributed equally to this work. Abstract: Bioethical and legal issues of three-dimensional (3D) bioprinting as the emerging field of biotechnology have not yet been widely discussed among bioethicists around the world, including Russia. The scope of 3D bioprinting includes not only the issues of the advanced technologies of human tissues and organs printing but also raises a whole layer of interdisciplinary problems of modern science, technology, bioethics, and philosophy. This article addresses the ethical and legal issues of bioprinting of artificial human organs. Keywords: Three-dimensional printing, Bioethics, Ethical issues, Regulatory concerns, Artificial ovary, Oncofertility *Corresponding Author: Anastasia Kirillova, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov of the Ministry of Healthcare of Russian Federation, Moscow, 117513, Russia; [email protected] Received: February 16, 2020; Accepted: March 16, 2020; Published Online: April 28, 2020 (This article belongs to the Special Section: Bioprinting in Russia) Citation: Kirillova
    [Show full text]
  • 3D Printing Technology and Innovations March 25-26, 2019 Rome, Italy
    conferenceseries.com 3rd International Conference on 3D Printing Technology and Innovations March 25-26, 2019 Rome, Italy SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM Monday, 25th March DAY 1 Monday, 25th March 08:30-09:00 Registrations 09:00-09:30 Introduction 09:30-09:50 COFFEE BREAK 09:50-11:50 KEYNOTE LECTURES Meeting Hall 01 MEETING HALL 01 MEETING HALL 02 11:50-13:10 Talks On: Talks On: Advances in 3D Printing & Additive Types of Cataract & Cataract Surgery Manufacturing Technology Stereolithography Bio printing tissues and organs Powder bed and inkjet head 3D printing Anatomical models for surgical preparation Laminated object manufacturing Customized implants and prostheses Digital light processing Drug delivery devices and dosage forms Selective laser melting Bone repair 13:10-13:15 GROUP PHOTO 13:15-14:00 LUNCH BREAK MEETING HALL 01 MEETING HALL 02 14:00-16:00 Talks On: 3D Bio printing Talks On: Innovations in 3D Printing 3D Bioprinting of Tissues and Organs 3D Printed Food Skin 3D Bioprinting 3D Printed shoes 3D bioprinting of Neural stem 3D Printed organs 3D bioprinting of Cell-Laden Microcarriers 3D Printing Redefining Air travel 3D bioprinting of human chondrocytes Consumer 3D Printing Bioprinting of 3D hydrogel 16:00-16:20 COFFEE BREAK MEETING HALL 01 (16:20-17:00) MEETING HALL 01 (17:00-18:00) Young Researchers Workshop https://3dprinting.insightconferences.com/ SCIENTIFIC PROGRAM Tuesday, 26th March DAY 2 Tuesday, 26th March 09:00-10:30 KEYNOTE LECTURES Meeting Hall 01 10:30-10:50 COFFEE BREAK MEETING HALL 01 MEETING HALL 02
    [Show full text]
  • 3D Bioprinting Technologies for Hard Tissue and Organ Engineering
    materials Review 3D Bioprinting Technologies for Hard Tissue and Organ Engineering Xiaohong Wang 1,2,*, Qiang Ao 1, Xiaohong Tian 1, Jun Fan 1, Yujun Wei 1, Weijian Hou 1, Hao Tong 1 and Shuling Bai 1 1 Department of Tissue Engineering, Center of 3D Printing & Organ Manufacturing, School of Fundamental Sciences, China Medical University (CMU), No. 77 Puhe Road, Shenyang North New Area, Shenyang 110122, China; [email protected] (Q.A.); [email protected] (X.T.); [email protected] (J.F.); [email protected] (Y.W.); [email protected] (W.H.); [email protected] (H.T.); [email protected] (S.B.) 2 Department of Mechanical Engineering, Tsinghua University, Center of Organ Manufacturing, Beijing 100084, China * Correspondence: [email protected] or [email protected]; Tel.: +86-189-0091-1302 Academic Editor: Chee Kai Chua Received: 31 July 2016; Accepted: 22 September 2016; Published: 27 September 2016 Abstract: Hard tissues and organs, including the bones, teeth and cartilage, are the most extensively exploited and rapidly developed areas in regenerative medicine field. One prominent character of hard tissues and organs is that their extracellular matrices mineralize to withstand weight and pressure. Over the last two decades, a wide variety of 3D printing technologies have been adapted to hard tissue and organ engineering. These 3D printing technologies have been defined as 3D bioprinting. Especially for hard organ regeneration, a series of new theories, strategies and protocols have been proposed. Some of the technologies have been applied in medical therapies with some successes. Each of the technologies has pros and cons in hard tissue and organ engineering.
    [Show full text]
  • Bioprinting Technology: a Current State-Of-The-Art Review
    Amer B. Dababneh Bioprinting Technology: Mechanical and Industrial Engineering Department, The University of Iowa, A Current State-of-the-Art Iowa City, IA 52242; Biomanufacturing Laboratory, Review Center for Computer-Aided Design, The University of Iowa, Bioprinting is an emerging technology for constructing and fabricating artificial tissue Iowa City, IA 52242 and organ constructs. This technology surpasses the traditional scaffold fabrication 1 approach in tissue engineering (TE). Currently, there is a plethora of research being Ibrahim T. Ozbolat done on bioprinting technology and its potential as a future source for implants and Mechanical and Industrial full organ transplantation. This review paper overviews the current state of the art in Engineering Department, bioprinting technology, describing the broad range of bioprinters and bioink used in The University of Iowa, preclinical studies. Distinctions between laser-, extrusion-, and inkjet-based bioprinting Iowa City, IA 52242; technologies along with appropriate and recommended bioinks are discussed. In Biomanufacturing Laboratory, addition, the current state of the art in bioprinter technology is reviewed with a focus on Center for Computer-Aided Design, the commercial point of view. Current challenges and limitations are highlighted, The University of Iowa, and future directions for next-generation bioprinting technology are also presented. Iowa City, IA 52242 [DOI: 10.1115/1.4028512] e-mail: [email protected] Keywords: bioprinting, bioink, tissue engineering 1 Introduction systems, such as laser-, extrusion-, and inkjet-based printing sys- tems. Given the huge number of cell types in the body, those bio- Since the first successful kidney transplant in 1954 was per- logically applied printing systems and technologies vary in their formed between two identical twins [1], organ transplantation has ability to ensure the deposition accuracy, stability, and viability of become a life-saving procedure for many disease conditions that cells.
    [Show full text]
  • Bioprinting of 3D Perfusable Structures Using an Extrusion-Based System
    Bioprinting of 3D Perfusable Structures Using an Extrusion-Based System by Prabhuti Kharel Bachelor of Science Biomedical Engineering Florida Institute of Technology 2013 A thesis submitted to the Graduate School of Florida Institute of Technology in partial fulfillment of the requirements for the degree of Masters of Science in Biomedical Engineering Melbourne, Florida June 2019 © Copyright 2019 Prabhuti Kharel All Rights Reserved The author grants permission to make single copies ___________________________________________ We the undersigned committee hereby approve the attached thesis, “Bioprinting of 3D Perfusable Structures Using an Extrusion Based System,” by Prabhuti Kharel _________________________________________________ Kunal Mitra, Ph.D. Professor, Biomedical Engineering Major Advisor _________________________________________________ Carlos Martino, Ph.D. Associate Professor, Biomedical Engineering _________________________________________________ James Brenner, Ph.D. Associate Professor, Chemical Engineering _________________________________________________ Ted Conway, Ph.D. Professor and Department Head Biomedical and Chemical Engineering and Sciences Abstract Bioprinting of 3D perfusable structures using an extrusion-based system By Prabhuti Kharel Principal Advisor: Kunal Mitra, Ph.D. Bioprinting is a technique of creating 3D cell laden structures by accurately dispensing biomaterial to form complex synthetic tissue. Bioprinting is a process of additive manufacturing where the cell functionality and viability is preserved within the printed structure. Bioprinting is a promising alternative to produce physiologically relevant 3D structures that mimic the native tissue. However, fabrication of complex structures with vascularization has been a major challenge in bioprinting. To overcome this challenge sacrificial printing in combination with fugitive inks has been explored to create vascularize structures. The objective of this study is to fabricate hollow channels within the bioprinted structure for vascularization using sacrificial printing.
    [Show full text]
  • 3D Bioprinting: the Roller Coaster Ride to Commercialization Anton Elemoso1*, Grigoriy Shalunov1*, Yakov M
    REVIEW ARTICLE 3D Bioprinting: The Roller Coaster Ride to Commercialization Anton Elemoso1*, Grigoriy Shalunov1*, Yakov M. Balakhovsky2, Alexander Yu. Ostrovskiy2,3, Yusef D. Khesuani1,2 1Laboratory of Biotechnical Research 3D Bioprinting Solutions, Moscow, Russian Federation 2Vivax Bio, LLC, New York, NY, USA 3Independent Laboratory IN VITRO, Moscow, Russian Federation Аbstract: Three-dimensional (3D) bioprinting as a technology is being researched and applied since 2003. It is actually several technologies (inkjet, extrusion, laser, magnetic bioprinting, etc.) under an umbrella term “3D bioprinting.” The versatility of this technology allows widespread applications in several; however, after almost 20 years of research, there is still a limited number of cases of commercialized applications. This article discusses the potential for 3D bioprinting in regenerative medicine, drug discovery, and food industry, as well as the existing cases of companies that create commercialized products and services in the aforementioned areas and even in fashion, including their go-to-market route and financing received. We also address the main barriers to creating practical applications of 3D bioprinting within each sphere the technology that is being studied for. Keywords: 3D bioprinting, Commercialization, Regenerative medicine, Drug discovery, Food *Corresponding Authors: Anton Elemoso, Laboratory of Biotechnical Research 3D Bioprinting Solutions, Moscow, Russian Federation; [email protected]/Grigoriy Shalunov, Laboratory of Biotechnical Research 3D Bioprinting Solutions, Moscow, Russian Federation; [email protected] Received: June 10, 2020; Accepted: June 23, 2020; Published Online: July 30, 2020 (This article belongs to the Special Section: Bioprinting in Russia) Citation: Elemoso A, Shalunov G, Balakhovsky YM, et al., 2020, 3D Bioprinting: The Roller Coaster Ride to Commercialization.
    [Show full text]
  • Matai 2020, Progress in 3D Bioprinting Technology for Tissue-Organ
    Biomaterials 226 (2020) 119536 Contents lists available at ScienceDirect Biomaterials journal homepage: www.elsevier.com/locate/biomaterials Review Progress in 3D bioprinting technology for tissue/organ regenerative T engineering Ishita Mataia, Gurvinder Kaura, Amir Seyedsalehib,c,d,f, Aneesah McClintonb,d, ∗ Cato T. Laurencinb,c,d,e,f,g, a Central Scientific Instruments Organization (CSIR-CSIO), Chandigarh, 160030, India b Connecticut Convergence Institute for Translation in Regenerative Engineering, UConn Health, Farmington, CT, USA c Department of Orthopedic Surgery, UConn Health, Farmington, USA d Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, UConn Health, Farmington, USA e Department of Materials Science and Engineering, University of Connecticut, Storrs, USA f Department of Biomedical Engineering, University of Connecticut, Storrs, USA g Department of Chemical and Biomolecular Engineering, University of Connecticut, Storrs, USA ARTICLE INFO ABSTRACT Keywords: Escalating cases of organ shortage and donor scarcity worldwide are alarming reminders of the need for alter- Tissue engineering natives to allograft tissues. Within the last three decades, research efforts in the field of regenerative medicine and Regenerative engineering tissue engineering continue to address the unmet need for artificial tissues and organs for transplant. Work inthe Artificial tissues field has evolved to create what we consider a new field, Regenerative Engineering, defined as the Convergenceof Three-dimensional
    [Show full text]
  • Recent Trends in Bioinks for 3D Printing Janarthanan Gopinathan1,2 and Insup Noh1,2*
    Gopinathan and Noh Biomaterials Research (2018) 22:11 https://doi.org/10.1186/s40824-018-0122-1 REVIEW Open Access Recent trends in bioinks for 3D printing Janarthanan Gopinathan1,2 and Insup Noh1,2* Abstract Background: The worldwide demand for the organ replacement or tissue regeneration is increasing steadily. The advancements in tissue engineering and regenerative medicine have made it possible to regenerate such damaged organs or tissues into functional organ or tissue with the help of 3D bioprinting. The main component of the 3D bioprinting is the bioink, which is crucial for the development of functional organs or tissue structures. The bioinks used in 3D printing technology require so many properties which are vital and need to be considered during the selection. Combination of different methods and enhancements in properties are required to develop more successful bioinks for the 3D printing of organs or tissue structures. Main body: This review consists of the recent state-of-art of polymer-based bioinks used in 3D printing for applications in tissue engineering and regenerative medicine. The subsection projects the basic requirements for the selection of successful bioinks for 3D printing and developing 3D tissues or organ structures using combinations of bioinks such as cells, biomedical polymers and biosignals. Different bioink materials and their properties related to the biocompatibility, printability, mechanical properties, which are recently reported for 3D printing are discussed in detail. Conclusion: Many bioinks formulations have been reported from cell-biomaterials based bioinks to cell-based bioinks such as cell aggregates and tissue spheroids for tissue engineering and regenerative medicine applications.
    [Show full text]